

# Journal of Visualized Experiments

## Endoscopic Minimally Invasive Intracerebral Hemorrhage Evacuation

--Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE58217R1
<b>Full Title:</b>	Endoscopic Minimally Invasive Intracerebral Hemorrhage Evacuation
<b>Keywords:</b>	intracerebral hemorrhage, hemorrhagic stroke, minimally invasive, endoscopic
<b>Corresponding Author:</b>	Christopher P Kellner Icahn School of Medicine at Mount Sinai New York, NY UNITED STATES
<b>Corresponding Author's Institution:</b>	Icahn School of Medicine at Mount Sinai
<b>Corresponding Author E-Mail:</b>	christopher.kellner@gmail.com
<b>Order of Authors:</b>	Jonathan S. Pan Alexander G. Chartrain Jacopo Scaggiante Olivia Allen Danny Hom Joshua B. Bederson J Mocco Christopher P. Kellner
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	1000 10th Ave., New York, NY 10019



**Cerebrovascular Center  
Department of Neurosurgery**

Mount Sinai Health System  
One Gustave L. Levy Place, Box 1136  
Klingenstein Clinical Center, 1-North  
1450 Madison Avenue  
New York, NY 10029

**Christopher P. Kellner, MD**

*Assistant Professor  
Director, Intracerebral Hemorrhage Program  
Department of Neurosurgery*

March 28, 2018

Dear JOVE editorial board,

Enclosed please find our manuscript entitled "Endoscopic Minimally Invasive Intracerebral Hemorrhage Evacuation." This manuscript describes how to perform this surgical procedure in a step by step manner. Multiple large international randomized trials demonstrated that traditional craniotomy with clot evacuation was not effective in improving outcome in this devastating disease process. Recent early-phase clinical trials, however, have renewed hope in the surgical treatment of intracerebral hemorrhage with preliminary data suggesting an outcome benefit when minimally invasive evacuation is performed. There are currently multiple phase 3 trials under way evaluating various minimally invasive techniques. With your videography experience, we hope to present a clear and comprehensive methodology that will become a resource for surgeons, physicians, scientists, and patients studying this new procedure.

We thank you in advance for your time and consideration.

Sincerely,

A handwritten signature in black ink that reads "Christopher Kellner". The signature is fluid and cursive, with the first name and last name clearly distinguishable.

Christopher P. Kellner, MD  
Assistant Professor of Neurosurgery  
Director of the Intracerebral Hemorrhage Program  
Icahn School of Medicine at Mount Sinai

**TITLE:**

Minimally Invasive Endoscopic Intracerebral Hemorrhage Evacuation

**AUTHORS AND AFFILIATIONS:**

Jonathan S. Pan, Alexander G. Chartrain, Jacopo Scaggiante, Olivia Allen, Danny Hom, Joshua B. Bederson, J Mocco, Christopher P. Kellner  
Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

**Corresponding Author:**

Christopher P. Kellner, MD  
christopher.kellner@mountsinai.org  
Tel: 617-365-2981

**Email Addresses of Co-authors:**

Jonathan S. Pan	(jonathan.pan@icahn.mssm.edu)
Alexander G. Chartrain	(alexander.chartrain@icahn.mssm.edu)
Jacopo Scaggiante	(jacopo.scaggiante@mountsinai.org)
Olivia Allen	(oallen@princeton.edu)
Danny Hom	(danny.hom@mountsinai.org)
Joshua B. Bederson	(joshua.bederson@mountsinai.org)
J Mocco	(j.mocco@mountsinai.org)

**KEYWORDS:**

Intracerebral hemorrhage, hemorrhagic stroke, minimally invasive, endoscopic, SCUBA, endoscope, ICH

**SUMMARY:**

This paper details the surgical protocol for minimally invasive endoscopic intracerebral hemorrhage evacuation using the SCUBA technique.

**ABSTRACT:**

Intracerebral hemorrhage (ICH) is a subtype of stroke with high mortality and poor functional outcomes, largely because there are no evidence-based treatment options for this devastating disease process. In the past decade, a number of minimally invasive surgeries have emerged to address this issue, one of which is endoscopic evacuation. Stereotactic ICH Underwater Blood Aspiration (SCUBA) is a novel endoscopic evacuation technique performed in a fluid-filled cavity using an aspiration system to provide an additional degree of freedom during the procedure. The SCUBA procedure utilizes a suction device, endoscope, and sheath and is divided into two phases. The first phase involves maximal aspiration and minimal irrigation to decrease clot burden. The second phase involves increasing irrigation for visibility, decreasing aspiration strength for targeted aspiration without disturbing the cavity wall, and cauterizing any bleeding vessels. Using the endoscope and aspiration wand, this technique aims to maximize hematoma evacuation while minimizing collateral damage to the surrounding brain. Advantages of the SCUBA technique

include the use of a low-profile endoscopic sheath minimizing brain disruption and improved visualization with a fluid-filled cavity rather than an air-filled one.

## **INTRODUCTION:**

Intracerebral hemorrhage is a bleed that occurs in the brain parenchyma and is the most devastating subtype of stroke in terms of mortality and disability. The worldwide incidence of ICH is approximately 24.6 per 100,000 individuals, with 40,000 to 67,000 cases occurring every year in the US<sup>1,2</sup>. Intracerebral hemorrhage is a medical emergency requiring fast diagnosis and management. Historically, outcomes have been bleak, with mortality rates of 40% at 1 month, 51-54% at 1 year, and 71% at 5 years<sup>3-6</sup>. A key reason for such a poor prognosis is that there are no evidence-based treatments for this disease process. Previous clinical trials (STICH I and II) did not demonstrate improved outcomes for surgery compared to conservative medical management<sup>7,8</sup>. A proposed hypothesis for the failure of craniotomies is that any benefit gained from evacuating the clot is outweighed by the extensive brain trauma inflicted by the invasive nature of the procedure. As a result, in the past decade, a number of minimally invasive techniques have been developed to attempt to solve this problem, each with advantages and disadvantages. The techniques can be grouped into two categories: stereotactic aspiration with thrombolysis and active evacuation. The former involves aspirating the clot through a burr hole, administering a thrombolytic agent, and draining the residual clot through a catheter over the period of several days. This technique is currently being tested in the MISTIE clinical trial and is used by clinicians in China with the YL-1 craniopuncture needle<sup>9,10</sup>. Active evacuation, on the other hand, involves aspirating the entire clot in a single procedure without the need for a draining catheter.

A number of clinical trials are also underway for this technique, including ENRICH, which utilizes the NICO BrainPath system for endoport-assisted trans-sulcal evacuation; the INVEST trial<sup>11</sup>, which is a single arm feasibility study using the Penumbra Apollo or Artemis Systems for endoscopic evacuation; and the MIND trial, which is a multicenter randomized clinical trial evaluating endoscopic evacuation using the Artemis device. Endoscopic evacuation is a promising technique because it has the lowest profile working channel to minimize brain trauma<sup>12</sup>. This paper outlines a specific endoscopic technique described as Stereotactic ICH Underwater Blood Aspiration (SCUBA)<sup>13</sup>. The first phase focuses on debulking the hematoma using maximal aspiration while working within the end of the sheath. The second phase utilizes a high irrigation rate to aspirate residual clots and cauterize any bleeding vessels in a highly targeted manner.

There are three devices used in the SCUBA procedure: a sheath (6.33 mm), endoscope, and aspiration system. The aspiration system consists of a surgical wand (2.6 mm) designed to fit inside the working channel of an endoscope, which is inserted into the sheath. The wand is capable of aspiration and, with the press of a button on the handle, morcellation. The morcellation component of the device is a spinning bident at the tip of the suction tube that spins upon activation. Suction is activated by covering the hole at the thumb on the handle, and the bident is activated by pressing firmly on the button. Suction activation in this regard is similar to common neurosurgical suction instruments.

## PROTOCOL:

Prior to performing this protocol, the required institutional approval and patient consent were obtained. All procedures were approved by Mount Sinai Hospital.

### 1. Inclusion Criteria

1.1. Include patients who meet all of the following criteria: age > 18 years old, baseline modified Rankin Scale (mRS) < 4, presenting Glasgow Coma Scale (GCS) > 4, presenting NIH Stroke Scale (NIHSS) ≥ 6, symptom onset < 24 hours prior to initial CT scan (minimally invasive ICH evacuation can be performed within 72 hours of ictus), supratentorial location of ICH, ICH volume > 20 cm<sup>3</sup>, stability in ICH volume measured on two CT scans 6 hours apart, systolic blood pressure controlled to < 160 mmHg for at least 6 hours prior to surgery.

### 2. Exclusion Criteria

2.1. Exclude patients who meet one or more of the following criteria: CT scan demonstrates expanding hemorrhage; spot sign on CTA imaging; underlying, unsecured lesion (*e.g.*, arteriovenous malformation, aneurysm, tumor); hemorrhagic conversion of an acute ischemic stroke; infratentorial location of ICH; large intraventricular hemorrhage requiring treatment as a result of mass effect or shift; extension of hemorrhage into the midbrain; absolute requirement for long-term anticoagulation; coagulopathy; platelet count < 100,000 cells/mm<sup>3</sup>; INR > 1.4; elevated activated partial thromboplastin time (aPTT); presenting GCS < 4, high risk for ischemic stroke; emergent need for surgical decompression; inability to give consent for the procedure; is pregnant, breast-feeding, or displays a positive pregnancy test; evidence of active infection; or any comorbid disease or condition expected to compromise survival.

### 3. Positioning and Planning

3.1. Administer general anesthesia to the patient using standard techniques.

3.2. Maintain sterile conditions throughout the entire procedure by sterilely preparing the skin and draping the surgical area.

3.3. Plan the trajectory of the evacuation by using preoperative volumetric imaging to draw a line along the long axis of the hematoma to the outer surface of the skull, so that the tip of the sheath will sit 1 to 2 cm from the distal end of the hematoma.

Note: Important things to keep in mind when planning the trajectory are to minimize disruption to brain tissue (especially eloquent structures) and avoid any vasculature visible on non-invasive imaging. Trajectory planning is performed on stereotactic navigation software, which varies by institution. A comparison of commonly used navigation systems in ICH evacuation is available in the medical literature<sup>14</sup>.

131 3.4. Place the patient in the correct anatomical position depending on the location of the  
132 hematoma.

133  
134 Note: Most cases (80%) are performed supine, and a minority are performed prone (15%) or  
135 supine with the head turned (5%).

#### 136 137 **4. Opening**

138  
139 4.1. Make a 2 cm linear, horizontal incision along the skin within a natural skin crease.

140  
141 4.2. Open the skull with a 1- to 1.2 cm-diameter craniectomy using a high-speed drill with a 5 mm  
142 cutting burr. Attempt to align the craniectomy with the long axis of the hematoma, but avoid  
143 midline structures and eloquent brain territories.

144  
145 Note: A perforator is larger than necessary, especially if the defect is on the forehead.

146  
147 4.3. If the trajectory is not perfectly perpendicular to the skull, drill a cylinder in the bone along  
148 the planned trajectory to ensure optimal mobility of the sheath and endoscope within the  
149 craniectomy, but be aware that the intersection with the dura will not be perpendicular.

150  
151 4.4. Use bone wax, gel foam in thrombin, and bipolar cautery to achieve hemostasis.

152  
153 4.5. Visualize the underlying hematoma using ultrasound to confirm its size and position.

154  
155 Note: Ultrasound quality is highest using the burr hole transducer in a wet field prior to  
156 durotomy.

157  
158 4.6. Open the dura in a cruciate fashion and cauterize the dural leaves to within a millimeter of  
159 the bone edge.

160  
161 Note: Avoid large veins or arteries.

162  
163 4.7. Incise the pia mater 1 cm with a #11 blade prior to cauterizing. If obtaining a brain biopsy,  
164 this is the ideal time. Use tumor forceps or the cup end of a Penfield 1 instrument. Avoid cautery  
165 until the biopsy is obtained.

166  
167 4.8. Cauterize the pial incision and underlying cortex with bipolar cautery.

#### 168 169 **5. Phase 1 Evacuation**

170  
171 5.1. Insert the introducer sheath along the planned trajectory with a navigation stylet positioned  
172 within the sheath. The stylet provides live feedback on the location of the tip.

Note: Given the small size of the 1 cm craniectomy, a “trans-sulcal” approach is often not possible; therefore, the pia is incised and entered in a non-vascular space immediately below the craniectomy.

5.2. If the clot is particularly fibrous and resistance is encountered, make a slight adjustment to the sheath to reach the target point.

5.3. Remove the introducer and navigation probe once the target point is reached, 1-2 cm from the distal end of the hematoma.

Note: Some operators prefer to use stereotactic navigation registered to the endoscope rather than the sheath introducer for continuous navigation.

5.4. Note the position of the sheath by marking it at the level of the skin.

Note: If the pressure within the hematoma is high, liquid may flow out of the sheath during this step.

5.5. Prepare the endoscope by activating the preferred settings including white balance, brightness, filter, and light intensity.

5.6. Attach the irrigation tubing from a 2 L saline bag at shoulder height to the left working port, and set the flow rate to approximately 25% on the endoscope. Open the right port of the endoscope all the way, allowing for egress of irrigation fluid.

5.7. Insert the endoscope into the sheath. Insert the wand inside the working channel of the endoscope and hold the wand with the dominant hand.

Note: For this phase of the procedure, maintain the endoscope and wand within the end of the sheath, approximately 0.5 to 2 cm from the end of the sheath.

5.8. Use the pointer finger to buffer the distance between endoscope and the wand’s handle to maintain constant awareness of the location of the tip of the device within the sheath.

5.9. Set the suction strength of the aspiration system to 100% and set the irrigation flow rate to low (~25%).

5.10. Aspirate any liquid hematoma that presents itself at the end of the sheath while keeping the wand within the distal 1 cm of the sheath.

Note: As the hematoma is aspirated, the cavity will collapse inward due to the reduced mass effect. Constant irrigation maintains the structure of the cavity during phase 2 of the evacuation.

5.11. If a solid clot is encountered that does not aspirate with suction alone, activate the bident within the wand to digest the clot.

5.12. If a piece of clot is too large or fibrous for suction and adheres to the tip of the wand, withdraw the entire endoscope and wand together with the clot, taking care not to dislodge the clot from the wand.

Note: This is called the ADAPT (A Direct Aspiration First Pass Technique) technique, referencing the practice of removing intravascular thrombus during thrombectomy for acute ischemic stroke<sup>15</sup>.

5.13. If the piece of clot is particularly large with a fibrous capsule and the prior two techniques do not work, use the working channel of the endoscope as an additional suction.

5.13.1. To accomplish this, attach a conventional surgical suction to the second endoscope port (usually the irrigation outflow pathway) with the valve closed but ready for activation. Draw the large piece of clot into the end of the sheath using the wand. Close the irrigation inflow port and open the outflow port to activate maximal surgical suction. The clot is now stuck on the tip of the wand, endoscope, and sheath. Remove the wand, endoscope, sheath, and clot together.

Note: This is called the double ADAPT technique.

5.14. If the clot has a fibrous capsule and is difficult to separate from the brain tissue, use the tip of the sheath as a blunt dissector.

Note: This is called the sheath dissection technique.

5.15. After aspirating, explore the cavity at the same depth by gently pivoting the sheath laterally until no residual clot remains at that depth.

5.16. Withdraw the sheath 1 cm and repeat the aspiration steps of Phase 1 until the sheath reaches the proximal wall of the cavity.

## **6. Phase 2 Evacuation**

6.1. Decrease the suction of the wand to 25% and increase the irrigation to 100% to improve visibility in the cavity. Explore for residual hematoma and identify bleeding arteries.

Note: During this phase, it is critical to minimize suction forces on the pericavity brain tissue.

6.2. Aspirate any residual hematoma in a targeted fashion with low aspiration power, taking care to not damage surrounding brain matter which can incur additional bleeding or cause trauma to the cavity wall.



Note: Blood products may initially interfere with optimal visualization but the cavity will clear with patient, continuous irrigation. If the cavity does not clear, identify and cauterize the bleeding vessels.

### 6.3. Monitor for any bleeding vessels and address them accordingly with the following steps:

6.3.1. If small bleeding vessels are challenging to visualize, direct a consistent flow of irrigation towards the vessel by hovering immediately over the bleeding site with the sheath and pulling the scope back from the tip. Once the vessel is better visualized, cauterize the vessel.

Note: This is called the sheath hover technique.

### 6.3.2. Irrigate the cavity until hemostasis is achieved

### 6.3.3. Apply pressure using the end of the sheath if pure irrigation does not work.

### 6.3.4. Utilize bipolar cautery if the previous two methods do not work.

### 6.3.5. Aspirate any residual hematoma along the sides or in the crevices of the cavity.

Note: This step becomes easier once the bleeding vessels are addressed, permitting clear visualization.

### 6.4. Ensure that the cavity is cleared of all visible hematomas and bleeding vessels.

Note: If there is a thin layer of fresh clot from intraoperative bleeding, beware of causing more bleeding in the attempted aspiration of this thin coating of fresh blood. Aspirate gently or leave the fresh blood in place. Differentiating clots from the cavity wall is a major challenge in the procedure.

## 7. Assessment and Closure

### 7.1. Withdraw the endoscope and sheath slowly, with the endoscope at the tip of the sheath to examine the tract walls upon exiting to monitor for additional bleeding.

Note: Some operators have advocated for infusing thrombin into the cavity at this point, either by adding thrombin directly to the irrigation fluid or by injecting gelatin mixed with thrombin through the endoscope. This is a reasonable option, but injecting gelatin mixed with thrombin will make ultrasound imaging impossible.

### 7.2. Use burr hole ultrasound to assess for residual hematoma or active bleeding.

Note: Ultrasound is useful for settling doubt about any questionable regions as well as detecting any large areas of residual hematoma that may have been missed under direct visualization.

**7.3. Perform an intraoperative Dyna-CT scan if available to evaluate the degree of evacuation.**

Note: The goal of the procedure is to obtain at least 80% evacuation. If there is more than 20% of the hematoma remaining, restart Phase 2 of the evacuation before proceeding to the following steps.

**7.4. Apply hemostatic gel foam in the burr hole over the surface of the brain.**

**7.5. Cover the craniectomy using a titanium plate and secure it using titanium screws.**

**7.6. Close the galea and subcutaneous layers using 3-0 polyglactin 910 sutures.**

**7.7. Close the skin using 4-0 poliglycaprone 25 subcuticular stitches, followed by skin closure surgical tape strips.**

#### **REPRESENTATIVE RESULTS:**

The SCUBA evacuation technique has been described in 47 patients undergoing endoscopic ICH evacuation between December 2015 and September 2017. The mean pre-operative ICH volume was reported as 42.6 cm<sup>3</sup> (standard deviation = 29.7 cm<sup>3</sup>; mean post-operative ICH volume = 4.2 cm<sup>3</sup>, SD 6.6 cm<sup>3</sup>), resulting in a mean evacuation rate of 88.2% (SD 20.8%) (**Table 1**). An example of pre-operative and post-operative CT scans is shown in **Figure 1**. In 23 (48.9%) cases, active bleeding vessels were detected, and in 12 (52.2%) of these cases, bleeding emanated from more than one vessel (**Table 2**). Bleeding was addressed using irrigation alone in 5 cases (10.6%) and electrocautery in 18 cases (38.3%) (**Table 2**). Post-operative bleeding was isolated to only a single case (2.1%) in which the routine head CT performed on post-operative day 1 demonstrated that the evacuation cavity had refilled with hemorrhage that appeared to originate from a superficial galeal vessel bleeding into the access tract and cavity (**Table 2**). This patient's examination did not worsen, and he did not require additional surgery.

#### **FIGURE LEGENDS:**

**Figure 1: CT scans.** (A) Pre-operative CT head image demonstrates a large right basal ganglia hemorrhage. (B) CT head image performed on post-operative day 1 demonstrates near-complete evacuation of the hematoma.

**Table 1: Evacuation details.** ICH volumes and evacuation rates for the SCUBA procedure.

**Table 2: Operative details.** Operative details (specifically bleeding vessels) encountered during the SCUBA procedure.

## DISCUSSION:

There are several operative best practices to learn and implement during endoscopic ICH evacuation. First and foremost, it is critical to minimize disruption to brain tissue whenever possible. Accomplishing this starts with optimizing the surgical trajectory so that the sheath traverses the shortest possible course while avoiding eloquent structures. For supratentorial ICH, eloquent structures include the supplementary motor area, primary motor and sensory cortices, left superior temporal and angular gyri, and primary visual cortex. In addition, the trajectory should align with the longitudinal axis of the hematoma. The benefits of this strategy include maximizing visualization of the cavity, minimizing torque force on the brain adjacent to the access tract, increasing the likelihood of being able to view the extremes of the cavity, and creating the shortest possible trajectory to the clot, thus minimizing brain trauma.

In addition to minimizing brain tissue disruption, it is also important to minimize distortion of the hematoma cavity. Aspiration in an enclosed cavity can distort elastic brain matter as much as compressive forces with equal damage. To avoid this, suction strength should be at the minimal possible level necessary for effective blood clot aspiration. This is especially important if the tip of the wand is advanced beyond the tip of the sheath. The only time the suction strength should be on high is during Phase 1, when the tip is in direct contact with the clot. The suction strength should decrease as the procedure progresses.

Unfavorable outcomes have been reported when irrigation during an endoscopic intraventricular hematoma evacuation leads to increased intracranial pressure<sup>16</sup>. The SCUBA procedure avoids this by evacuating the hematoma in Phase 1, which decreases pressure within the cavity, and subsequently irrigating in Phase 2. In Phase 2, the endoscope has a second access port that allows for irrigation outflow, thus avoiding over-distension of the hematoma cavity and elevated intracavitary pressure. In addition, the sheath and tract do not form a watertight seal and irrigation fluid is lost around the sheath.

Achieving and maintaining hemostasis during Phase 2 is a crucial requirement for a successful SCUBA evacuation. It is important to meticulously monitor every wall of the cavity for bleeding vessels and address them accordingly with continuous irrigation or bipolar cautery. Achieving perfect hemostasis ensures that there is minimal risk of postoperative re-bleeding.

Since clear, direct visualization of the residual hematoma within the cavity may not always be possible during the procedure, it is a best practice to check the evacuation with intraoperative imaging after Phase 2. There have been several cases in which direct endoscopic examination suggested that the cavity was clear but residual hematoma was detected on either intraoperative ultrasound or DYNA CT, leading to another pass with the sheath into the cavity and additional hematoma evacuation.

At this early stage in the development of this procedure, there is strong enough evidence to suggest what the lower limit of evacuation percentage of residual clot volume should be. Though there are currently no studies evaluating outcomes for endoscopic procedure evacuation percentages, animal models and the MISTIE trial suggest that increased evacuation is preferred<sup>9</sup>.

In ICH-induced mice, molecules in the blood such as iron had a toxic effect on the surrounding brain tissue, while iron chelators reduced the damage<sup>17</sup>. The MISTIE II trial found that perihematomal edema volume was smallest when evacuation percentage exceeded 65%, larger when evacuation percentage ranged from 20-65%, and largest when evacuation percentage was less than 20%<sup>18</sup>. This data also suggest that outcome may improve with higher evacuation percentage, but the study was not powered to assess this feature. The MISTIE phase III, ENRICH, INVEST, and/or MIND trials may shed light on this question.

One area that remains to be resolved is the timeframe of the procedure. Many protocols advocate evacuation within 72 hours and after a 6-hour stability scan to ensure that the hematoma is stable. Many physicians choose this course of action, as a small study from 2004 reported complications, re-bleeding, and poor outcomes in a small series of patients who underwent craniotomy for ultra-early surgery<sup>19</sup>. More recent studies on minimally invasive endoscopic evacuation have reported good outcomes with ultra-early evacuation<sup>20,21</sup>. Manuscripts reporting endoscopic evacuation suggest that bleeding is identifiable and controllable in ultra-early evacuations. The ENRICH study protocol requires evacuation within 24 hours of ictus and does not mandate a stability scan. Ultra-early surgery may be an option in the future, but additional studies are necessary to assess the risks and benefits of ultra-early evacuation.

The SCUBA procedure is a minimally invasive intracerebral hemorrhage evacuation technique that involves an endoscope using an aspiration system. Preliminary evidence suggests that the SCUBA technique can be performed safely and reliably results in a high evacuation percentage. Further studies are necessary to assess the impact of this procedure on functional outcomes.

#### **ACKNOWLEDGMENTS:**

This research was supported in part by a grant from Arminio and Lucyna Fraga and a grant from Mr. and Mrs. Durkovic.

#### **DISCLOSURES:**

Christopher Kellner received an educational grant from Penumbra for a CME course to teach endoscopic minimally invasive intracerebral hemorrhage evacuation. J Mocco is a co-principal investigator on the INVEST trial, which is a feasibility study to evaluate endoscopic minimally invasive intracerebral hemorrhage evacuation funded by Penumbra. J Mocco is an investor and consultant for Rebound Therapeutics.

#### **REFERENCES**

1. van Asch, C.J.J., Luitse, M.J.A., Rinkel, G.J.E., van der Tweel, I., Algra, A., Klijn, C.J.M. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurology*. **9** (2), 167–176 (2010).
2. Qureshi, A.I., Mendelow, A.D., Hanley, D.F. Intracerebral haemorrhage. *Lancet*. **373** (9675), 1632–1644 (2009).

3. Aguilar, M.I., Freeman, W.D. Spontaneous intracerebral hemorrhage. *Seminars in Neurology*. **30** (5), 555–564 (2010).
4. Broderick, J., *et al.* Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. *Circulation*. **116** (16), e391–413 (2007).
5. Caceres, J.A., Goldstein, J.N. Intracranial hemorrhage. *Emergency Medicine Clinics of North America*. **30** (3), 771–794 (2012).
6. Poon, M.T.C., Fonville, A.F., Al-Shahi Salman, R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. *Journal of Neurology, Neurosurgery, and Psychiatry*. **85** (6), 660–667 (2014).
7. Mendelow, A.D., Gregson, B.A., Rowan, E.N., Murray, G.D., Gholkar, A., Mitchell, P.M. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. *Lancet*. **382** (9890), 397–408 (2013).
8. Mendelow, A.D., *et al.* Early surgery *versus* initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. *Lancet Neurology*. **365** (9457), 387–397 (2005).
9. Hanley, D.F., *et al.* Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. *Lancet Neurology*. **15** (12), 1228–1237 (2016).
10. Wang, W.-Z., *et al.* Minimally invasive craniopuncture therapy vs. conservative treatment for spontaneous intracerebral hemorrhage: results from a randomized clinical trial in China. *International Journal of Stroke*. **4** (1), 11–16 (2009).
11. Fiorella, D., Arthur, A.S., Mocco, J.D. The INVEST Trial: A Randomized, Controlled Trial to Investigate the Safety and Efficacy of Image-Guided Minimally Invasive Endoscopic Surgery With Apollo vs .... *Neurosurgery*. (2016).
12. Fiorella, D., Arthur, A., Bain, M., Mocco, J. Minimally Invasive Surgery for Intracerebral and Intraventricular Hemorrhage: Rationale, Review of Existing Data and Emerging Technologies. *Stroke*. **47** (5), 1399–1406 (2016).
13. Kellner, C.P., *et al.* The Stereotactic Intracerebral Hemorrhage Underwater Blood Aspiration (SCUBA) technique for minimally invasive endoscopic intracerebral hemorrhage evacuation. *Journal of NeuroInterventional Surgery*. (2018).
14. Chartrain, A.G., *et al.* A review and comparison of three neuronavigation systems for minimally invasive intracerebral hemorrhage evacuation. *Journal of NeuroInterventional Surgery*. (2017).
15. Turk, A.S., *et al.* ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy. *Journal of NeuroInterventional Surgery*. **6** (4), 260–264 (2014).
16. Trnovec, S., Halatsch, M.-E., Putz, M., Behnke-Mursch, J., Mursch, K. Irrigation can cause prolonged intracranial pressure elevations during endoscopic treatment of intraventricular haematomas. *British Journal of Neurosurgery*. **26** (2), 247–251 (2012).

- 477 17. Wu, H., Wu, T., Xu, X., Wang, J., Wang, J. Iron toxicity in mice with collagenase-induced  
478 intracerebral hemorrhage. *Journal of Cerebral Blood Flow & Metabolism*. **31** (5), 1243–1250  
479 (2011).
- 480 18. Mould, W.A., *et al.* Minimally invasive surgery plus recombinant tissue-type plasminogen  
481 activator for intracerebral hemorrhage evacuation decreases perihematoma edema. *Stroke*. **44**  
482 (3), 627–634 (2013).
- 483 19. Morgenstern, L.B., Demchuk, A.M., Kim, D.H., Frankowski, R.F., Grotta, J.C. Rebleeding  
484 leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. *Neurology*. **56**  
485 (10), 1294–1299 (2001).
- 486 20. Nishihara, T., *et al.* Newly developed endoscopic instruments for the removal of  
487 intracerebral hematoma. *Neurocritical Care*. **2** (1), 67–74 (2005).
- 488 21. Nagasaka, T., Inao, S., Ikeda, H., Tsugeno, M., Okamoto, T. Inflation-deflation method for  
489 endoscopic evacuation of intracerebral haematoma. *Acta Neurochirurgica*. **150** (7), 685–90  
490 (2008).
- 491




Table 1: Evacuation Details

Variable	Mean	Standard Deviation
Preoperative Volume	42.6	29.7
Postoperative Volume	4.2	6.6
Evacuation Percentage	88.2%	20.8%



Table 2: Operative Details

Variable	Number	Percent
Total Patients	47	-
Active Bleeding Identified	23	48.9%
Single Vessels	11	23.4%
Multiple Vessels	12	25.5%
Irrigation	5	10.6%
Electrocautery	18	38.3%
Postoperative Bleeding	1	2.1%

<b>Name of Material/ Equipment</b>	<b>Company</b>	<b>Catalog Number</b>
Artemis Device 2.8mm	Penumbra Inc.	AP28
Artemis Device 2.1mm	Penumbra Inc.	AP21
Artemis Device 1.5mm	Penumbra Inc.	AP15
MAX Canister	Penumbra Inc.	APCAN2
Pump MAX 110V	Penumbra Inc.	PMX110
19-French Sheath	Aesculap USA	FH604SU
Storz Lotta 3-port Endoscope	Karl Storz	28164 LA / 28164 LS
Medtronic AxiEM	Medtronic	UC201403939
High-speed drill with 5-mm cutting burr	Medtronic	9BA60
Bone Wax	Ethicon	W31
Hemostatic Gel Foam with Thrombin	J&J Healthcare	2994
Bipolar Cautery	State of the Art	401102
Aloka burr hole ultrasound transducer	Aloka	UST-52114P
11-blade	Bard Parker	372611
Penfield 1 instrument	Sklar Corp	47-2255
AxiEM stylet	Medtronic	9735428
Titanium plate	Depuy Synthes	04503023/04503024
Titanium screws	Depuy Synthes	0450310301/0450310401
DYNA CT on the Artis Q	Siemens Healthineers	A91AX-01343-33C1-7600
3-0 Vicryl sutures	Ethicon	J416
4-0 monocril subcuticular stitches	Ethicon	Y426
Steri-Strips	3M	R1547

**Comments/Description**

Cannula Outer Diameter: 2.8mm. Cannula Length: 27cm. Aspiration Tubing Length: 9.5ft; The Food

Cannula Outer Diameter: 2.1mm. Cannula Length: 26cm. Aspiration Tubing Length: 9.5ft

Cannula Outer Diameter: 1.5mm. Cannula Length: 27cm. Aspiration Tubing Length: 9.5ft

Outer Diameter: 6.33mm

Outer Diameter: 6.1mm. Two ports for irrigation/suction (1.6mm). One working channel (2.9mm)

An advantage of the Medtronic AxiEM system is it does not require pinning or line-of-site navigation.

l and Drug Administration (FDA) approved the Apollo System in 2014 for use in intraventricular hemorrhage (I

VH) evacuation but its indication now includes ICH and the Artemis System was approved for the same IVH &

and ICH evacuation in 2017.



1 Alewife Center #200  
 Cambridge, MA 02140  
 tel. 617.945.9051  
[www.jove.com](http://www.jove.com)

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Endoscopic Minimally Invasive Intracerebral Hemorrhage Evacuation

Author(s):

Jonathan Pan, Alex G. Chartrain, Jacopo Scaggiante, Danny Homm, Joshua B. Bederson,  
 J Mocco, Christopher P. Kellner

Item 1 (check one box): The Author elects to have the Materials be made available (as described at  
<http://www.jove.com/author>) via: ☐ Standard Access ☒ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's


expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name:	Christopher P. Kellner	
Department:	Neurosurgery	
Institution:	Icahn School of Medicine at Mount Sinai	
Article Title:	Endoscopic Minimally Invasive Intracerebral Hemorrhage Evacuation	
Signature:		Date: 3/23/18

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051

Christopher Kellner, MD  
Department of Neurosurgery  
Icahn School of Medicine at Mount Sinai  
Phone: (212) 241-2606  
Email: christopher.kellner@mountsinai.org

July 9, 2018

Dear Reviewers,

Thank you for your detailed review and inquiries. Below we include a point by point response to your concerns with referenced changes to the manuscript. All changes have been tracked and any changes addressing your specific concerns have been highlighted in yellow.

**Reviewer #1:**

**Manuscript Summary:**

*There are many nuances in performing a truly minimally invasive hematoma evacuation with a endoscope. This manuscript has described most of the detail in this procedure, and it is quite suitable for a visualized publication.*

**Major Concerns:**

*Line 133: "3.5.2. Attempt to enter a sulcus if possible."*

*Line 141: "4.1.1. If possible, the insertion point should be made within a sulcus to minimize gyral neuronal column injury."*

*When a sulcus is just right on the burr hole, insert the sheath in a sulcus will increase the bleeding risk. So the sulcus should be avoid except there is enough space for a surgeon to split the arachnid and reach the bottom of the sulcus, which usually you won't have in a 1-1.2cm craniectomy.*

*Personally, I prefer to make the cut right beside the sulcus, and insert the sheath along the sulcus and cling the pia.*

Thank you for your review and comments. We have taken them into account and made the following updates.

We acknowledge that a transsulcal approach is often difficult to perform. We have updated the protocol to now read "Given the small size of the 1cm craniectomy, a "trans-sulcal" approach is often not possible and therefore the pia is incised and entered in a non-vascular space immediately below the craniectomy." (highlighted in yellow)

**Minor Concerns:**

*Line 144: "4.2. Remove the introducer and navigation probe once you reach the target point, 1.5cm from the distal end of the hematoma."*

*Sometimes, the clot is fibrous and not easy to be penetrated. If this step is done by force, additional injury can be caused by inexperienced surgeon at the distal part of the hematoma cavity.*

*Therefore, a check point should be added when the tip of the sheath touch the clot surface. If there are some resistance come from the sheath, the surgeon should slightly adjust the penetrating point and find the weak spot, or insert the endoscope to evacuate the blocking clot.*

This concern has been addressed with the following line: "If the clot is particularly fibrous and resistance is encountered, make a slight adjustment to the sheath to reach the target point." (highlighted in yellow)

***And the safest way should be inserting the transparent sheath with the endoscope placed inside and mounted with navigation system, so that the whole procedure is performed with direct vision.***

Excellent point.

While we prefer to use a navigated probe and find that method safe and effective, we acknowledge many operators prefer to use stereotactic navigation registered to the endoscope rather the sheath introducer for continuous navigation. We have added the following line “Some operators prefer to use stereotactic navigation registered to the endoscope rather the sheath introducer for continuous navigation.” (highlighted in yellow)

***Reviewer #2:***

***Manuscript Summary:***

***this is an interesting, relevant and well written manuscript***

***Major Concerns:***

***none***

***Minor Concerns:***

***The authors state that there was no increase in ICP or intracavitary pressure during their 2 phase procedure. Is this published yet? Do they have data?***

***„5.1.1. We have monitored intracavitary pressure during this phase of the procedure and there is no appreciable intracavitary local pressure increase.”***

While we do have data, we have not yet published it and appreciate your point. We have removed this line from the manuscript.

***Why do you think you reduce damage via a transsulcal approach? Is there any evidence or what is the reasoning?***

We agree that while some operators attempt to perform a trans-sulcal approach, there is no evidence that this is beneficial. We have updated the protocol to now read “Given the small size of the 1cm craniectomy, a “trans-sulcal approach is often not possible and therefore the pia is incised and entered in a non-vascular space immediately below the craniectomy.” (highlighted in yellow)

***Reviewer #3:***

***Manuscript Summary:***

***I have already finish reading this article***

***And I highly recommend it***

Thank you for your review and comments.

***Reviewer #4:***

***The only items I might suggest adding to the manuscript are a summary of technical challenges for folks learning the procedure and a summary of when this procedure should and should not be used.***

Thank you for your review and comments.

Challenges and the proper way to address them have been included throughout the protocol. In addition, the discussion summarizes important tenets for surgeons to keep in mind when learning and performing the procedure (highlighted in yellow). Also, the inclusion and exclusion criteria for the procedure have now been included to address when this procedure should and should not be used (highlighted in yellow).